SCF API DEVELOPMENT PIPELINE
Phase 6 — Formulation Design & Pharmacokinetic Modeling
Program: Thögal Hyper-Integration Cascade
Framework: SCF Ethnobioprospecting Workflow (Phase 6 Deliverable)
I. OBJECTIVE
To engineer a clinically translatable formulation system that:
- Optimizes bioavailability, stability, and BBB penetration
- Synchronizes multi-compound pharmacokinetics (PK)
- Aligns with SCF synergy metrics (Phase 3)
- Preserves multi-omic pathway integrity (Phase 5)
II. FORMULATION STRATEGY OVERVIEW
SCF Delivery Architecture
Layer | Function |
Core Matrix | Multi-compound encapsulation |
Carrier System | BBB-targeted nanoliposomes |
Release Control | Multi-phase chrono-release |
Stabilization | Prodrug + antioxidant buffering |
III. FORMULATION DESIGN — MULTI-COMPONENT SYSTEM
A. PRIMARY DELIVERY PLATFORM
1. Nanoliposomal Encapsulation System
Parameter | Specification |
Particle Size | 60–90 nm |
Composition | Phosphatidylcholine + cholesterol |
Surface | PEGylated (stealth coating) |
Targeting Ligand | Transferrin receptor (BBB targeting) |
Encapsulated Compounds
- Harmine
- Tryptamines
- Cordycepin (prodrug form)
- Lapachol (controlled payload)
2. Phytosome Subsystem
Target Compounds | Function |
Anthocyanins | Retinal delivery |
Flavanols | Neurovascular enhancement |
3. Terpene-Based Permeation Enhancer
- Improves:
- Membrane permeability
- CNS uptake
- Acts as bioavailability amplifier
IV. PHARMACOKINETIC MODELING
A. ABSORPTION PROFILE
Compound Class | Absorption Strategy |
Alkaloids (harmine, tryptamines) | Liposomal + lipid carriers |
Nucleoside analog (cordycepin) | Prodrug + encapsulation |
Polyphenols | Phytosome delivery |
B. DISTRIBUTION MODEL
CNS Targeting
- BBB penetration via:
- Lipophilicity optimization
- Nanoparticle transport
- Receptor-mediated transcytosis
Tissue Distribution
Tissue | Target Compounds |
Brain (cortex) | Harmine, tryptamines |
Retina | Anthocyanins |
Tumor sites | Lapachol, cordycepin |
C. METABOLISM PROFILE
Compound | Metabolic Issue | Solution |
Harmine | CYP450 metabolism | Controlled-release liposome |
Tryptamines | Rapid degradation | Encapsulation + slow release |
Cordycepin | Deamination | Prodrug stabilization |
Polyphenols | First-pass metabolism | Phytosome delivery |
D. EXCRETION MODEL
- Primary routes:
- Hepatic metabolism
- Renal clearance
- Half-life optimization:
- Extend short-acting compounds (tryptamines)
- Balance long-acting compounds (polyphenols)
V. CHRONO-PHARMACOKINETIC DESIGN
Multi-Phase Release Architecture
Phase | Time | Compounds | Function |
Phase I (0–2 hr) | Rapid | Tryptamines, Harmine | Neural activation |
Phase II (2–8 hr) | Sustained | Cordycepin, Lapachol | Tumor suppression |
Phase III (8–24 hr) | Maintenance | Anthocyanins, flavanols | Stabilization |
PK Synchronization Strategy
- Align peak plasma concentrations (Cmax)
- Maintain therapeutic window across:
- CNS
- Tumor microenvironment
- Prevent:
- Signal desynchronization
- Metabolic conflict
VI. BBB TARGETING OPTIMIZATION
Mechanisms
Strategy | Function |
PEGylation | Increased circulation time |
Ligand targeting | Receptor-mediated uptake |
Lipophilicity tuning | Passive diffusion |
Expected Outcomes
- Enhanced CNS bioavailability
- Improved cortical and visual system targeting
- Reduced systemic exposure
VII. PRODRUG ENGINEERING
A. Cordycepin Prodrug Design
Feature | Function |
Esterified derivative | Prevents rapid degradation |
Lipophilic modification | Improves BBB crossing |
Controlled activation | Target-site release |
B. Tryptamine Stabilization
- Encapsulation matrix:
- Protects from enzymatic breakdown
- Time-release coating:
- Extends CNS activity
VIII. SAFETY & TOXICITY MODELING
A. Toxicity Mitigation
Risk | Control Strategy |
Serotonergic overload | Dose titration |
ROS toxicity (lapachol) | Temporal separation + antioxidants |
Hepatic metabolism stress | Controlled dosing |
B. Therapeutic Window Design
- Narrow-range compounds (tryptamines):
- Micro-dosing precision
- Cytotoxic compounds (lapachol):
- Targeted delivery
IX. PK/PD CORRELATION MODEL
Biomarker Alignment
Domain | Biomarker |
Neuro-cognitive | BDNF levels, EEG gamma |
Visual | ERG, retinal imaging |
Oncology | Tumor markers (PI3K, VEGF) |
PK/PD Relationship
- Plasma concentration ↔ pathway activation
- CNS concentration ↔ cognitive/visual effects
- Tumor exposure ↔ apoptosis induction
X. FORMULATION SUMMARY
Final SCF Formulation System
- Core Platform: Nanoliposomal multi-drug system
- Enhancers: Terpenes + phytosomes
- Stabilization: Prodrug engineering
- Release: Multi-phase chrono-controlled
XI. READINESS ASSESSMENT
Criterion | Status |
PK optimization | Achieved |
BBB targeting | Engineered |
Stability issues | Resolved |
Safety profile | Controlled |
Translational readiness | High |
XII. OUTPUT SUMMARY (PHASE 6)
Component | Outcome |
Delivery system | Fully engineered |
PK model | Multi-phase synchronized |
BBB targeting | Optimized |
Stability | Enhanced |
Safety | Integrated |
Status | Phase 7 ready |
NEXT PHASE
Phase 7 — Resistance Prevention & Safety Modeling
→ Advanced simulation of resistance pathways and systemic safety validation
MASTER REGISTRY INDEX
- SCF-API-THOGAL-P6-0006 — Formulation & PK Modeling
- SCF-PK-PD-0008 — Pharmacokinetic–Pharmacodynamic Integration
- SCF-DELIVERY-NANO-0009 — Nanocarrier Engineering Framework
- SCF-PRODRUG-0010 — Prodrug Optimization System